Drug intelligence / Profile preview

MK-8294

Development stage: Phase 1
Lead developer: Merck
Administration: Intravenous

Overview

MK-8294 is an **investigational anticancer agent** currently being studied in a phase 1 clinical trial for participants with advanced solid tumors. It is being developed by Merck Sharp & Dohme LLC (Merck). As of now, detailed information regarding its **mechanism of action, molecular target, and specific modality** has not been publicly disclosed. The drug is in early-phase clinical development, and its precise pharmacological class and intended molecular targets remain unspecified in the available sources[2][4][7][9][10].

Other names: MK-8294MK8294MK 8294

Beyond the preview

Go deeper on MK-8294.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-8294.

Explore the full profile